1551 - 1600 of 8399 Results
Title
Year
-
OPENTitle: Pharmacological Mechanism of the Non-hallucinogenic 5-HT2A Agonist Ariadne and AnalogsJournal Name: ACS Chemical NeurosciencePublisher: American Chemical Society (ACS)Vol: 14Issue #: 1Start Page: 119End Page: 135Publication Date:Open Access(OA) Status: OPENLicense:DOI - Digital Object Identifier: 10.1021/acschemneuro.2c00597Best OA location URL: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10147382Citation Count: 37
- Hippocampal, basal ganglia and olfactory connectivity contribute to cognitive impairments in Parkinson's disease2022OPENTitle: Hippocampal, basal ganglia and olfactory connectivity contribute to cognitive impairments in Parkinson's diseaseJournal Name: European Journal of NeurosciencePublisher: WileyVol: 57Issue #: 3Start Page: 511End Page: 526Publication Date:Open Access(OA) Status: OPENLicense:DOI - Digital Object Identifier: 10.1111/ejn.15899Citation Count: 13
-
OPENTitle: Membrane curvature sensing and stabilization by the autophagic LC3 lipidation machineryJournal Name: Science AdvancesPublisher: American Association for the Advancement of Science (AAAS)Vol: 8Issue #: 50Start Page:End Page:Publication Date:Open Access(OA) Status: OPENLicense: cc-by-nc, cc-by-ncDOI - Digital Object Identifier: 10.1126/sciadv.add1436Best OA location URL: https://www.science.org/doi/pdf/10.1126/sciadv.add1436?download=trueCitation Count: 36
-
OPENTitle: Plasma phosphorylated tau181 predicts cognitive and functional declineJournal Name: Annals of Clinical and Translational NeurologyPublisher: WileyVol: 10Issue #: 1Start Page: 18End Page: 31Publication Date:Open Access(OA) Status: OPENLicense: cc-by-nc-ndDOI - Digital Object Identifier: 10.1002/acn3.51695Best OA location URL: https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/acn3.51695Citation Count: 17
- Proximity to residential and workplace pesticides application and the risk of progression of Parkinson's diseases in Central California2022OPENTitle: Proximity to residential and workplace pesticides application and the risk of progression of Parkinson's diseases in Central CaliforniaJournal Name: Science of The Total EnvironmentPublisher: Elsevier BVVol: 864Issue #:Start Page: 160851End Page: 160851Publication Date:Open Access(OA) Status: OPENLicense: cc-by-nc-ndDOI - Digital Object Identifier: 10.1016/j.scitotenv.2022.160851Best OA location URL: https://doi.org/10.1016/j.scitotenv.2022.160851Citation Count: 25
-
OPENTitle: Nomogram to Predict the Probability of Functional Dependence in Early Parkinson’s DiseaseJournal Name: Journal of Parkinson’s DiseasePublisher: SAGE PublicationsVol: 13Issue #: 1Start Page: 49End Page: 55Publication Date:Open Access(OA) Status: OPENLicense: cc-byDOI - Digital Object Identifier: 10.3233/jpd-223501Best OA location URL: https://content.iospress.com:443/download/journal-of-parkinsons-disease/jpd223501?id=journal-of-parkinsons-disease%2Fjpd223501Citation Count: 3
- Predicting longitudinal brain atrophy in Parkinson’s disease using a Susceptible-Infected-Removed agent-based model2022OPENTitle: Predicting longitudinal brain atrophy in Parkinson’s disease using a Susceptible-Infected-Removed agent-based modelJournal Name: Network NeurosciencePublisher: MIT PressVol: 7Issue #: 3Start Page: 906End Page: 925Publication Date:Open Access(OA) Status: OPENLicense: cc-byDOI - Digital Object Identifier: 10.1162/netn_a_00296Best OA location URL: https://direct.mit.edu/netn/article-pdf/doi/10.1162/netn_a_00296/2074404/netn_a_00296.pdfCitation Count: 11
- Association of Sodium–Glucose Cotransporter 2 Inhibitors With Time to Dementia: A Population-Based Cohort Study2022OPENTitle: Association of Sodium–Glucose Cotransporter 2 Inhibitors With Time to Dementia: A Population-Based Cohort StudyJournal Name: Diabetes CarePublisher: American Diabetes AssociationVol: 46Issue #: 2Start Page: 297End Page: 304Publication Date:Open Access(OA) Status: OPENLicense:DOI - Digital Object Identifier: 10.2337/dc22-1705Best OA location URL: https://diabetesjournals.figshare.com/articles/figure/Association_of_sodium-glucose_cotransporter-2_inhibitors_with_time_to_dementia_a_population-based_cohort_study/21445284/1/files/38063811.pdfCitation Count: 69
-
OPENTitle: Isolated Jaw and Tongue Tremor in a Definite Case of Progressive Supranuclear PalsyJournal Name: Movement Disorders Clinical PracticePublisher: WileyVol: 10Issue #: 2Start Page: 348End Page: 349Publication Date:Open Access(OA) Status: OPENLicense:DOI - Digital Object Identifier: 10.1002/mdc3.13640Best OA location URL: https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/mdc3.13640Citation Count: 0
-
RESTRICTEDTitle: LRRK2-targeted Parkinson disease drug advances into phase IIIJournal Name: Nature Reviews Drug DiscoveryPublisher: Springer Science and Business Media LLCVol: 22Issue #: 1Start Page: 3End Page: 5Publication Date:Open Access(OA) Status: RESTRICTEDLicense:DOI - Digital Object Identifier: 10.1038/d41573-022-00212-0Citation Count: 8
- Predictive modelling of Parkinson’s disease progression based on RNA-Sequence with densely connected deep recurrent neural networks2022OPENTitle: Predictive modelling of Parkinson’s disease progression based on RNA-Sequence with densely connected deep recurrent neural networksJournal Name: Scientific ReportsPublisher: Springer Science and Business Media LLCVol: 12Issue #: 1Start Page:End Page:Publication Date:Open Access(OA) Status: OPENLicense: cc-byDOI - Digital Object Identifier: 10.1038/s41598-022-25454-1Best OA location URL: https://www.nature.com/articles/s41598-022-25454-1.pdfCitation Count: 5
-
OPENTitle: The genetic regulation of protein expression in cerebrospinal fluidJournal Name: EMBO Molecular MedicinePublisher: Springer Science and Business Media LLCVol: 15Issue #: 1Start Page:End Page:Publication Date:Open Access(OA) Status: OPENLicense: cc-byDOI - Digital Object Identifier: 10.15252/emmm.202216359Best OA location URL: https://onlinelibrary.wiley.com/doi/pdfdirect/10.15252/emmm.202216359Citation Count: 35
- Chemosensory Dysfunction 3-Months After COVID-19, Medications and Factors Associated with Complete Recovery2022OPENTitle: Chemosensory Dysfunction 3-Months After COVID-19, Medications and Factors Associated with Complete RecoveryJournal Name: Annals of Otology, Rhinology & LaryngologyPublisher: SAGE PublicationsVol: 132Issue #: 10Start Page: 1177End Page: 1185Publication Date:Open Access(OA) Status: OPENLicense:DOI - Digital Object Identifier: 10.1177/00034894221138485Best OA location URL: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9742352Citation Count: 2
- It Is as It Was: MDS‐UPDRS Part III Scores Cannot Be Combined with Other Parts to Give a Valid Sum2022OPENTitle: It Is as It Was: MDS‐UPDRS Part III Scores Cannot Be Combined with Other Parts to Give a Valid SumJournal Name: Movement DisordersPublisher: WileyVol: 38Issue #: 2Start Page: 342End Page: 347Publication Date:Open Access(OA) Status: OPENLicense:DOI - Digital Object Identifier: 10.1002/mds.29279Best OA location URL: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9974855Citation Count: 10
-
OPENTitle: Tailoring Motor Fluctuation Treatment: Beyond Levodopa Dose AdjustmentJournal Name: European Medical JournalPublisher: European Medical GroupVol:Issue #:Start Page: 20End Page: 27Publication Date:Open Access(OA) Status: OPENLicense: cc-by-ncDOI - Digital Object Identifier: 10.33590/emj/10022165Best OA location URL: https://www.emjreviews.com/wp-content/uploads/2022/12/Tailoring-Motor-Fluctuation-Treatment-Beyond-Levodopa-Dose-Adjustment-1.pdfCitation Count: 0
- Brain vitamin D forms, cognitive decline, and neuropathology in community‐dwelling older adults2022OPENTitle: Brain vitamin D forms, cognitive decline, and neuropathology in community‐dwelling older adultsJournal Name: Alzheimer's & DementiaPublisher: WileyVol: 19Issue #: 6Start Page: 2389End Page: 2396Publication Date:Open Access(OA) Status: OPENLicense: cc-by-ncDOI - Digital Object Identifier: 10.1002/alz.12836Best OA location URL: https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/alz.12836Citation Count: 16
- Discovery and Optimization of Potent, Selective, and Brain-Penetrant 1-Heteroaryl-1H-Indazole LRRK2 Kinase Inhibitors for the Treatment of Parkinson’s Disease2022RESTRICTEDTitle: Discovery and Optimization of Potent, Selective, and Brain-Penetrant 1-Heteroaryl-1H-Indazole LRRK2 Kinase Inhibitors for the Treatment of Parkinson’s DiseaseJournal Name: Journal of Medicinal ChemistryPublisher: American Chemical Society (ACS)Vol: 65Issue #: 24Start Page: 16801End Page: 16817Publication Date:Open Access(OA) Status: RESTRICTEDLicense:DOI - Digital Object Identifier: 10.1021/acs.jmedchem.2c01605Citation Count: 13
-
OPENTitle: Spectrum of Pediatric to Early Adulthood POLR3A‐Associated Movement DisordersJournal Name: Movement Disorders Clinical PracticePublisher: WileyVol: 10Issue #: 2Start Page: 316End Page: 322Publication Date:Open Access(OA) Status: OPENLicense:DOI - Digital Object Identifier: 10.1002/mdc3.13635Citation Count: 2
-
OPENTitle: A Severe Case of Lupus CerebritisJournal Name: NeurologyPublisher: Ovid Technologies (Wolters Kluwer Health)Vol: 99Issue #: 23_Supplement_2Start Page:End Page:Publication Date:Open Access(OA) Status: OPENLicense:DOI - Digital Object Identifier: 10.1212/01.wnl.0000903100.95793.8aBest OA location URL: https://n.neurology.org/content/neurology/99/23_Supplement_2/S9.full.pdfCitation Count: 1
- An Observational Study on the Humoral and Cellular Immune Response to SARS-CoV-2 mRNA Vaccination in Multiple Sclerosis and Other Autoimmune Neurological Disorders Treated With Anti-CD20 Therapies2022OPENTitle: An Observational Study on the Humoral and Cellular Immune Response to SARS-CoV-2 mRNA Vaccination in Multiple Sclerosis and Other Autoimmune Neurological Disorders Treated With Anti-CD20 TherapiesJournal Name: NeurologyPublisher: Ovid Technologies (Wolters Kluwer Health)Vol: 99Issue #: 23_Supplement_2Start Page:End Page:Publication Date:Open Access(OA) Status: OPENLicense:DOI - Digital Object Identifier: 10.1212/01.wnl.0000903428.98962.0aBest OA location URL: https://n.neurology.org/content/neurology/99/23_Supplement_2/S52.full.pdfCitation Count: 1
- Brain and Cerebrospinal Fluid α‐Synuclein Real‐Time Quaking‐Induced Conversion Identifies Lewy Body Pathology in LRRK2‐PD2022OPENTitle: Brain and Cerebrospinal Fluid α‐Synuclein Real‐Time Quaking‐Induced Conversion Identifies Lewy Body Pathology in LRRK2‐PDJournal Name: Movement DisordersPublisher: WileyVol: 38Issue #: 2Start Page: 333End Page: 338Publication Date:Open Access(OA) Status: OPENLicense: cc-byDOI - Digital Object Identifier: 10.1002/mds.29284Best OA location URL: https://doi.org/10.1002/mds.29284Citation Count: 19
- Examining the Differences in Biomarkers of Neuronal and Glial Injury Between Autoimmune Neurologic Disease Patients and Healthy Controls2022OPENTitle: Examining the Differences in Biomarkers of Neuronal and Glial Injury Between Autoimmune Neurologic Disease Patients and Healthy ControlsJournal Name: NeurologyPublisher: Ovid Technologies (Wolters Kluwer Health)Vol: 99Issue #: 23_Supplement_2Start Page:End Page:Publication Date:Open Access(OA) Status: OPENLicense:DOI - Digital Object Identifier: 10.1212/01.wnl.0000903096.36040.1dBest OA location URL: https://n.neurology.org/content/neurology/99/23_Supplement_2/S8.full.pdfCitation Count: 0
- Genome-wide association study of REM sleep behavior disorder identifies polygenic risk and brain expression effects2022OPENTitle: Genome-wide association study of REM sleep behavior disorder identifies polygenic risk and brain expression effectsJournal Name: Nature CommunicationsPublisher: Springer Science and Business Media LLCVol: 13Issue #: 1Start Page:End Page:Publication Date:Open Access(OA) Status: OPENLicense: cc-by, cc-byDOI - Digital Object Identifier: 10.1038/s41467-022-34732-5Best OA location URL: https://www.nature.com/articles/s41467-022-34732-5.pdfCitation Count: 47
- Protective Association of HLA-DRB1*04 Subtypes in Neurodegenerative Diseases Implicates Acetylated Tau PHF6 Sequences2022OPENTitle: Protective Association of HLA-DRB1*04 Subtypes in Neurodegenerative Diseases Implicates Acetylated Tau PHF6 SequencesJournal Name: NeurologyPublisher: Ovid Technologies (Wolters Kluwer Health)Vol: 99Issue #: 23_Supplement_2Start Page:End Page:Publication Date:Open Access(OA) Status: OPENLicense:DOI - Digital Object Identifier: 10.1212/01.wnl.0000903160.72715.2dBest OA location URL: https://n.neurology.org/content/neurology/99/23_Supplement_2/S17.1.full.pdfCitation Count: 1
- Safety, Efficacy, And Pharmacokinetics of Argx-117 in Adults With Multifocal Motor Neuropathy: A Global, Multicenter, Placebo Controlled Phase 2 Study (Arda)2022OPENTitle: Safety, Efficacy, And Pharmacokinetics of Argx-117 in Adults With Multifocal Motor Neuropathy: A Global, Multicenter, Placebo Controlled Phase 2 Study (Arda)Journal Name: NeurologyPublisher: Ovid Technologies (Wolters Kluwer Health)Vol: 99Issue #: 23_Supplement_2Start Page:End Page:Publication Date:Open Access(OA) Status: OPENLicense:DOI - Digital Object Identifier: 10.1212/01.wnl.0000903320.23411.f9Best OA location URL: https://n.neurology.org/content/neurology/99/23_Supplement_2/S40.full.pdfCitation Count: 1
-
OPENTitle: Substitution of PINK1 Gly411 modulates substrate receptivity and turnoverJournal Name: AutophagyPublisher: Informa UK LimitedVol: 19Issue #: 6Start Page: 1711End Page: 1732Publication Date:Open Access(OA) Status: OPENLicense: cc-byDOI - Digital Object Identifier: 10.1080/15548627.2022.2151294Best OA location URL: https://doi.org/10.1080/15548627.2022.2151294Citation Count: 18
- The ExTINGUISH Trial: A Phase-2B Randomized Placebo-Controlled Trial of Inebilizumab in Anti-NMDA Receptor Encephalitis2022OPENTitle: The ExTINGUISH Trial: A Phase-2B Randomized Placebo-Controlled Trial of Inebilizumab in Anti-NMDA Receptor EncephalitisJournal Name: NeurologyPublisher: Ovid Technologies (Wolters Kluwer Health)Vol: 99Issue #: 23_Supplement_2Start Page:End Page:Publication Date:Open Access(OA) Status: OPENLicense:DOI - Digital Object Identifier: 10.1212/01.wnl.0000903316.50895.83Best OA location URL: https://n.neurology.org/content/neurology/99/23_Supplement_2/S39.full.pdfCitation Count: 2
- Understanding Correlation of Electroclinical Findings With Functional and Neuropsychiatric Outcomes in Patients with LGI1-Encephalitis2022RESTRICTEDTitle: Understanding Correlation of Electroclinical Findings With Functional and Neuropsychiatric Outcomes in Patients with LGI1-EncephalitisJournal Name: NeurologyPublisher: Ovid Technologies (Wolters Kluwer Health)Vol: 99Issue #: 23_Supplement_2Start Page:End Page:Publication Date:Open Access(OA) Status: RESTRICTEDLicense:DOI - Digital Object Identifier: 10.1212/01.wnl.0000903424.19914.85Citation Count: 0
- Persistent depressive symptoms are associated with frontal regional atrophy in patients with Alzheimer's disease2022OPENTitle: Persistent depressive symptoms are associated with frontal regional atrophy in patients with Alzheimer's diseaseJournal Name: International Journal of Geriatric PsychiatryPublisher: WileyVol: 38Issue #: 1Start Page:End Page:Publication Date:Open Access(OA) Status: OPENLicense:DOI - Digital Object Identifier: 10.1002/gps.5858Best OA location URL: https://research-information.bris.ac.uk/files/352878234/depression_AD_neuroimaging_paper_int_j_ger_psych_rev_2_clean.pdfCitation Count: 8
-
OPENTitle: Synapsin III Regulates Dopaminergic Neuron Development in VertebratesJournal Name: CellsPublisher: MDPI AGVol: 11Issue #: 23Start Page: 3902End Page: 3902Publication Date:Open Access(OA) Status: OPENLicense: cc-byDOI - Digital Object Identifier: 10.3390/cells11233902Best OA location URL: https://www.mdpi.com/2073-4409/11/23/3902/pdf?version=1669977075Citation Count: 2
-
RESTRICTEDTitle: Bile acids and neurological diseaseJournal Name: Pharmacology & TherapeuticsPublisher: Elsevier BVVol: 240Issue #:Start Page: 108311End Page: 108311Publication Date:Open Access(OA) Status: RESTRICTEDLicense: cc-by, cc-byDOI - Digital Object Identifier: 10.1016/j.pharmthera.2022.108311Best OA location URL: https://doi.org/10.1016/j.pharmthera.2022.108311Citation Count: 12
- Collaboration and knowledge integration for successful brain therapeutics – lessons learned from the pandemic2022OPENTitle: Collaboration and knowledge integration for successful brain therapeutics – lessons learned from the pandemicJournal Name: Disease Models & MechanismsPublisher: The Company of BiologistsVol: 15Issue #: 12Start Page:End Page:Publication Date:Open Access(OA) Status: OPENLicense: cc-byDOI - Digital Object Identifier: 10.1242/dmm.049755Best OA location URL: https://doi.org/10.1242/dmm.049755Citation Count: 0
- Impairment of amacrine starburst cells and their synaptic contacts with dopaminergic cells could explain motion perception disturbances in Parkinson's disease2022RESTRICTEDTitle: Impairment of amacrine starburst cells and their synaptic contacts with dopaminergic cells could explain motion perception disturbances in Parkinson's diseaseJournal Name: Acta OphthalmologicaPublisher: WileyVol: 100Issue #: S275Start Page:End Page:Publication Date:Open Access(OA) Status: RESTRICTEDLicense:DOI - Digital Object Identifier: 10.1111/j.1755-3768.2022.0786Citation Count: 0
- Increased post-mitotic senescence in aged human neurons is a pathological feature of Alzheimer’s disease2022OPENTitle: Increased post-mitotic senescence in aged human neurons is a pathological feature of Alzheimer’s diseaseJournal Name: Cell Stem CellPublisher: Elsevier BVVol: 29Issue #: 12Start Page: 1637End Page: 1652.e6Publication Date:Open Access(OA) Status: OPENLicense: publisher-specific-oaDOI - Digital Object Identifier: 10.1016/j.stem.2022.11.010Best OA location URL: https://doi.org/10.1016/j.stem.2022.11.010Citation Count: 115
-
OPENTitle: Machine learning‐based prediction of cognitive outcomes in de novo Parkinson's diseaseJournal Name: Alzheimer's & DementiaPublisher: WileyVol: 18Issue #: S5Start Page:End Page:Publication Date:Open Access(OA) Status: OPENLicense:DOI - Digital Object Identifier: 10.1002/alz.067067Best OA location URL: http://bura.brunel.ac.uk/bitstream/2438/27655/1/FullText.pdfCitation Count: 5
- Molecular heterogeneity in the substantia nigra: A roadmap for understanding PD motor pathophysiology2022RESTRICTEDTitle: Molecular heterogeneity in the substantia nigra: A roadmap for understanding PD motor pathophysiologyJournal Name: Neurobiology of DiseasePublisher: Elsevier BVVol: 175Issue #:Start Page: 105925End Page: 105925Publication Date:Open Access(OA) Status: RESTRICTEDLicense: cc-by-nc-nd, cc-by-nc-ndDOI - Digital Object Identifier: 10.1016/j.nbd.2022.105925Best OA location URL: https://doi.org/10.1016/j.nbd.2022.105925Citation Count: 12
-
RESTRICTEDTitle: Nano drug delivery systems for antisense oligonucleotides (ASO) therapeuticsJournal Name: Journal of Controlled ReleasePublisher: Elsevier BVVol: 352Issue #:Start Page: 861End Page: 878Publication Date:Open Access(OA) Status: RESTRICTEDLicense:DOI - Digital Object Identifier: 10.1016/j.jconrel.2022.10.050Citation Count: 34
-
RESTRICTEDTitle: Orchestration of selective autophagy by cargo receptorsJournal Name: Current BiologyPublisher: Elsevier BVVol: 32Issue #: 24Start Page: R1357End Page: R1371Publication Date:Open Access(OA) Status: RESTRICTEDLicense: cc-by, cc-byDOI - Digital Object Identifier: 10.1016/j.cub.2022.11.002Best OA location URL: https://doi.org/10.1016/j.cub.2022.11.002Citation Count: 36
-
RESTRICTEDTitle: P5B-ATPases in the mammalian polyamine transport system and their role in diseaseJournal Name: Biochimica et Biophysica Acta (BBA) - Molecular Cell ResearchPublisher: Elsevier BVVol: 1869Issue #: 12Start Page: 119354End Page: 119354Publication Date:Open Access(OA) Status: RESTRICTEDLicense: publisher-specific-oa, publisher-specific-oaDOI - Digital Object Identifier: 10.1016/j.bbamcr.2022.119354Best OA location URL: https://doi.org/10.1016/j.bbamcr.2022.119354Citation Count: 12
-
RESTRICTEDTitle: Parkinson’s disease drug hunters think outside the α-synuclein boxJournal Name: Nature BiotechnologyPublisher: Springer Science and Business Media LLCVol: 40Issue #: 12Start Page: 1705End Page: 1707Publication Date:Open Access(OA) Status: RESTRICTEDLicense:DOI - Digital Object Identifier: 10.1038/s41587-022-01610-wCitation Count: 1
-
RESTRICTEDTitle: Pompe disease treated before birthJournal Name: Nature BiotechnologyPublisher: Springer Science and Business Media LLCVol: 40Issue #: 12Start Page: 1707End Page: 1707Publication Date:Open Access(OA) Status: RESTRICTEDLicense:DOI - Digital Object Identifier: 10.1038/s41587-022-01621-7Citation Count: 2
-
OPENTitle: Precision medicine for Parkinson’s disease: The subtyping challengeJournal Name: Frontiers in Aging NeurosciencePublisher: Frontiers Media SAVol: 14Issue #:Start Page:End Page:Publication Date:Open Access(OA) Status: OPENLicense: cc-byDOI - Digital Object Identifier: 10.3389/fnagi.2022.1064057Best OA location URL: https://www.frontiersin.org/articles/10.3389/fnagi.2022.1064057/pdfCitation Count: 8
- Protective association of HLA‐DRB1*04 subtypes in neurodegenerative diseases implicates acetylated tau PHF6 sequences2022RESTRICTEDTitle: Protective association of HLA‐DRB1*04 subtypes in neurodegenerative diseases implicates acetylated tau PHF6 sequencesJournal Name: Alzheimer's & DementiaPublisher: WileyVol: 18Issue #: S3Start Page:End Page:Publication Date:Open Access(OA) Status: RESTRICTEDLicense:DOI - Digital Object Identifier: 10.1002/alz.060159Citation Count: 1
- REM sleep behavior and olfactory dysfunction: Enhancing the utility and translation of animal models in the search for precision medicines for Parkinson's disease2022RESTRICTEDTitle: REM sleep behavior and olfactory dysfunction: Enhancing the utility and translation of animal models in the search for precision medicines for Parkinson's diseaseJournal Name: Neuroscience & Biobehavioral ReviewsPublisher: Elsevier BVVol: 143Issue #:Start Page: 104897End Page: 104897Publication Date:Open Access(OA) Status: RESTRICTEDLicense:DOI - Digital Object Identifier: 10.1016/j.neubiorev.2022.104897Citation Count: 1
-
RESTRICTEDTitle: Roc, the G-domain of the Parkinson’s disease-associated protein LRRK2Journal Name: Trends in Biochemical SciencesPublisher: Elsevier BVVol: 47Issue #: 12Start Page: 1038End Page: 1047Publication Date:Open Access(OA) Status: RESTRICTEDLicense: publisher-specific-oaDOI - Digital Object Identifier: 10.1016/j.tibs.2022.06.009Best OA location URL: http://manuscript.elsevier.com/S0968000422001633/pdf/S0968000422001633.pdfCitation Count: 7
-
OPENTitle: Structural basis for Parkinson’s disease-linked LRRK2’s binding to microtubulesJournal Name: Nature Structural & Molecular BiologyPublisher: Springer Science and Business Media LLCVol: 29Issue #: 12Start Page: 1196End Page: 1207Publication Date:Open Access(OA) Status: OPENLicense: cc-by, cc-by, cc-byDOI - Digital Object Identifier: 10.1038/s41594-022-00863-yBest OA location URL: https://www.nature.com/articles/s41594-022-00863-y.pdfCitation Count: 38
-
RESTRICTEDTitle: Volitional Control of Brain Motor Activity and Its Therapeutic PotentialJournal Name: Neuromodulation: Technology at the Neural InterfacePublisher: Elsevier BVVol: 25Issue #: 8Start Page: 1187End Page: 1196Publication Date:Open Access(OA) Status: RESTRICTEDLicense:DOI - Digital Object Identifier: 10.1016/j.neurom.2022.01.007Best OA location URL: https://discovery.ucl.ac.uk/10146442/3/Foltynie_Volitional%20Control%20of%20Motor%20Brain%20Activity%20-%2002.11.21.pdfCitation Count: 7
- Discriminative binding of tau PET tracers PI2620, MK6240 and RO948 in Alzheimer’s disease, corticobasal degeneration and progressive supranuclear palsy brains2022OPENTitle: Discriminative binding of tau PET tracers PI2620, MK6240 and RO948 in Alzheimer’s disease, corticobasal degeneration and progressive supranuclear palsy brainsJournal Name: Molecular PsychiatryPublisher: Springer Science and Business Media LLCVol: 28Issue #: 3Start Page: 1272End Page: 1283Publication Date:Open Access(OA) Status: OPENLicense: cc-byDOI - Digital Object Identifier: 10.1038/s41380-022-01875-2Best OA location URL: https://www.nature.com/articles/s41380-022-01875-2.pdfCitation Count: 42
- Practically Defined Off‐State Dyskinesia Following Repeated Intraputamenal Glial Cell Line–Derived Neurotrophic Factor Administration2022OPENTitle: Practically Defined Off‐State Dyskinesia Following Repeated Intraputamenal Glial Cell Line–Derived Neurotrophic Factor AdministrationJournal Name: Movement DisordersPublisher: WileyVol: 38Issue #: 1Start Page: 104End Page: 112Publication Date:Open Access(OA) Status: OPENLicense: cc-by-nc-ndDOI - Digital Object Identifier: 10.1002/mds.29262Best OA location URL: https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/mds.29262Citation Count: 4
-
OPENTitle: Regulation of Αlpha-Synuclein Gene (SNCA) by Epigenetic Modifier TET1 in Parkinson DiseaseJournal Name: International Neurourology JournalPublisher: Korean Continence SocietyVol: 26Issue #: Suppl 2Start Page: S85End Page: 93Publication Date:Open Access(OA) Status: OPENLicense: cc-by-ncDOI - Digital Object Identifier: 10.5213/inj.2222206.103Best OA location URL: https://www.einj.org/upload/pdf/inj-2222206-103.pdfCitation Count: 9